Switch to:
GuruFocus has detected 1 Warning Sign with Novo Nordisk A/S $NVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Novo Nordisk A/S (NYSE:NVO)
Research & Development
$2,131 Mil (TTM As of Mar. 2017)

This is the expense the company spent on research and development. Novo Nordisk A/S's research and development for the three months ended in Mar. 2017 was $473 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2017 was $2,131 Mil.


Definition

This is the expense the company spent on research and development.

Novo Nordisk A/S Research & Development for the trailing twelve months (TTM) ended in Mar. 2017 was 503.096209032 (Jun. 2016 ) + 520.861575538 (Sep. 2016 ) + 633.826782372 (Dec. 2016 ) + 472.876798988 (Mar. 2017 ) = $2,131 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Novo Nordisk A/S Annual Data

Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
Research & Development 1,6691,4251,5401,7041,7031,9162,1562,2801,9862,065

Novo Nordisk A/S Quarterly Data

Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16Mar17
Research & Development 640471457495589493503521634473
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

FEEDBACK